Big Picture – A Deep Dive Examination of ANGLE PLC
ANGLE PLC Snapshot
UK, North America & Canada.
Garth Selvey Non Executive Chairman
Garth Selvey has a BSc in Physics and Electronics Engineering from the University of Manchester and has spent thirty six years in the computer industry with technical, product, sales and marketing roles. He became Managing Director of TIS Applications Ltd in 1984 and a main board director of TIS Ltd prior to its acquisition by Misys in 1989.
He organised the management buyout of the social housing division of Misys and became Group Chief Executive of Comino Group plc when it floated on AIM in 1997. Comino moved to a full listing in 1999 where he remained until its successful public sale to Civica plc in February 2006. Garth joined ANGLE as a Non-executive Director in September 2006.
Andrew Newland Chief Executive
Andrew Newland is the founder and Chief Executive of ANGLE plc. For over twenty five years, he has specialised in building technology-based businesses based on strong intellectual property and for the last fifteen years he has been Chairman or on the Board of several specialist medical technology companies. Andrew has an MA in Engineering Science from the University of Cambridge, and is a qualified Chartered Accountant.
After working with the engineering conglomerate, TI plc, he worked for KPMG from 1982 to 1994; from 1985 to 1987 he was based in the US as a manager providing corporate finance and business advice to high technology firms in the area around Route 128, Boston, Massachusetts. During this time, he led KPMG’s involvement in the IPO of the medical technology company Cardio Data Inc. From 1987 to 1994 he worked for KPMG in the UK with responsibility for establishing KPMG’s UK and European High Technology Practices and High Technology Consulting Group. Andrew founded ANGLE in 1994. Together with ANGLE’s senior management team, Andrew has co-founded and led eleven technology companies in partnership with world class research organisations, both in the UK and the US. Andrew has been instrumental in developing and then delivering the business proposition for these companies, building management teams, raising finance and securing revenues. In 1999, Andrew led the team that founded the medical diagnostic company, Acolyte Biomedica. Acolyte was the first ever spin-out of dstl Porton Down, which specialised in rapid diagnosis of MRSA the ‘hospital super-bug’. Andrew chaired the company for several years and successfully led the company through three major rounds of venture capital investment. Andrew also founded Provexis, the first ever spin-out of Rowett Institute, Europe’s leading nutrition research institute. Andrew chaired the Board of Provexis, a specialist nutraceutical company with a heart-health product, through to its successful flotation in 2005.
Ian Griffiths Finance Director
Ian Griffiths is the Finance Director of ANGLE plc. He has specialised in technology commercialisation for over twenty years and is an expert on the development and growth of new technology based businesses. Ian has a BSc in Mathematics with Management Applications from Brunel University and is qualified as a chartered accountant. For seven years he worked for KPMG, initially in accountancy, then in management consulting within KPMG’s High Technology Consulting Group where he specialised in financial modelling, business planning, corporate finance, market development and strategy work.
He joined ANGLE in 1995. As well as leading the finance function at ANGLE plc, he has been closely involved with the development and delivery of the UK, US and Middle East Consulting and Management businesses and in developing new Ventures, both third party and ANGLE’s own. Ian has been heavily involved in the start-up phase and also the ongoing development of ANGLE’s own ventures by working closely with management on business plans, financial and operational management, fund raising and commercial aspects, including both medical and physical sciences companies. He is currently leading the financial development of ANGLE’s major medical diagnostic business Parsortix.
Brian Howlett Non Executive Director
Brian Howlett has a wealth of international experience as a medtech leader which he is currently applying in a Non-Executive / Chairman capacity for surgical graft company Vascular Flow Technologies Ltd, skin cancer imaging company Michelson Diagnostics Ltd and medical device coating and surface modification company Accentus Medical Ltd, as well as ANGLE plc. Brian was formerly CEO of Lombard Medical Technologies PLC, an AIM listed company specialising in stents for abdominal aortic aneurysms from 2005 to 2009.
During his tenure significant capital was raised to fund the development of operations to commercialise the Aorfix stent graft towards regulatory approvals and growing revenues in EU, USA, Russia and Brazil. Corporate experience includes six years as UK Country Leader of Boston Scientific Ltd, between 1999 and 2005, during which time major medical devices such as the TAXUS drug eluting stent were launched driving sales and profits to the point where the UK and Ireland subsidiary became one of the leading revenue contributors to the Corporation’s European operations. Between 1987 and 1999, Brian was Managing Director of the UK sales and manufacturing subsidiary of Cobe Laboratories Inc. In addition, Brian spent almost 20 years in the pharmaceutical industry, gaining strong sales and marketing experience through a number of senior management positions in UK, Scandinavia and the Benelux markets within Fisons plc. Brian joined ANGLE as a Non-executive Director in January 2013.
Dr Jan Groen Non Executive Director
Dr Jan Groen is currently the Chief Executive Officer of MDxHealth, a genomic diagnostics company that improves the lives of patients by reducing diagnostic ambiguity in urological cancers. MDxHealth’s genomic tests are setting new standards in prostate and bladder cancer diagnosis, where they have helped over 100,000 patients avoid unnecessary diagnostic procedures.
His career spans over 25 years in clinical diagnostics and life science global markets. Dr. Groen was previously the President and COO of Agendia, responsible for their United States and European diagnostic operations, respectively. Dr. Groen is (co)-founder of ViroClinics and DxOrange and has held numerous management and scientific positions at Focus Diagnostics, a subsidiary of Quest Diagnostics, the Erasmus Medical Center, and Akzo-Nobel. He has had board mandates in several diagnostic companies. Currently he serves on the board of SPL Medical in the Netherlands. He holds a Ph.D. degree in Medical Microbiology from the Erasmus University Rotterdam, a BSc in Clinical Laboratory Studies and has published more than 125 papers in international scientific journals in the field of clinical diagnostics.
Shares in issue: 143,486,522 10p Ords
|Significant Shareholders (>3%)||Date||Amount||Holding %|
|Jupiter Asset Management Limited||13/11/2018||20,080,840||13.99%|
|Legal & General||08/11/2018||10,093,439||7.03%|
|Fidelity International Limited||8,944,382||6.23%|
10 Nugent Road,
The Surrey Research Park,
50 Ronson Drive, Suite 105,
Toronto, Ontario, M9W 1B3,
416 798 1625
RSM UK Audit LLP
25 High Street
West Sussex RH10 1BG
T +44 (0)845 057 0700
PO Box 1 2nd Floor,
G3 2 Cathedral Hill
GU1 3ZR T
+44 (0)1483 739540
Solicitors / Lawyers
30 Crown Place
EC2A 4ES T
+44 (0)207 418 7000
Financial Public Relations
F T I Consulting
T +44 (0)20 3727 1390
Link Asset Services
34 Beckenham Road
Kent BR3 4TU
T +44 (0)871 664 0300
(Calls cost 10p per minute plus
Nominated Advisor & Broker
60 New Broad Street
London EC2M 1JJ
T +44 (0)20 7220 050
WG Partners LLP
85 Gresham Street
London EC2V 7NQ
+44 (0)203 705 9316